Author:
Zhang Mu-Chen,Tian Shuang,Fu Di,Wang Li,Cheng Shu,Yi Hong-Mei,Jiang Xu-Feng,Song Qi,Zhao Yan,He Yang,Li Jian-Feng,Mu Rong-Ji,Fang Hai,Yu Hao,Xiong Hui,Li Biao,Chen Sai-Juan,Xu Peng-Peng,Zhao Wei-Li
Reference59 articles.
1. Cancer statistics, 2019;Siegel;CA A Cancer J. Clin.,2019
2. Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma;Vitolo;J. Clin. Oncol.,2017
3. Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial;Xu;Lancet. Haematol.,2019
4. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma;Younes;J. Clin. Oncol.,2019
5. ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma;Nowakowski;J. Clin. Oncol.,2021
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献